Sartorius Financial Statements From 2010 to 2024
| 56S1 Stock | EUR 183.30 1.10 0.60% |
Check Sartorius Stedim financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sartorius Stedim's main balance sheet or income statement drivers, such as , as well as many indicators such as . Sartorius financial statements analysis is a perfect complement when working with Sartorius Stedim Valuation or Volatility modules.
Sartorius |
Sartorius Stedim Biotech Company Current Valuation Analysis
Sartorius Stedim's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Sartorius Stedim Current Valuation | 31.28 B |
Most of Sartorius Stedim's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sartorius Stedim Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Sartorius Stedim Biotech has a Current Valuation of 31.28 B. This is 117.79% higher than that of the Healthcare sector and 242.13% higher than that of the Medical Instruments & Supplies industry. The current valuation for all Germany stocks is 88.17% lower than that of the firm.
Sartorius Stedim Biotech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sartorius Stedim's current stock value. Our valuation model uses many indicators to compare Sartorius Stedim value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sartorius Stedim competition to find correlations between indicators driving Sartorius Stedim's intrinsic value. More Info.Sartorius Stedim Biotech is rated third in return on equity category among its peers. It is rated second in return on asset category among its peers reporting about 0.37 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Sartorius Stedim Biotech is roughly 2.68 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sartorius Stedim's earnings, one of the primary drivers of an investment's value.About Sartorius Stedim Financial Statements
Sartorius Stedim stakeholders use historical fundamental indicators, such as Sartorius Stedim's revenue or net income, to determine how well the company is positioned to perform in the future. Although Sartorius Stedim investors may analyze each financial statement separately, they are all interrelated. For example, changes in Sartorius Stedim's assets and liabilities are reflected in the revenues and expenses on Sartorius Stedim's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Sartorius Stedim Biotech. Please read more on our technical analysis and fundamental analysis pages.
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG. SARTOR STED operates under Medical Instruments Supplies classification in Germany and is traded on Frankfurt Stock Exchange. It employs 8200 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Sartorius Stock
Sartorius Stedim financial ratios help investors to determine whether Sartorius Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sartorius with respect to the benefits of owning Sartorius Stedim security.